Drugs / ABSK112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06225804 | Feb 2024 → Mar 2027 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Abbisko Therapeutics Co, Ltd | Results 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 (pan-KRAS) abbisko.com ↗
Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors. |
| 2023-10-27 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutic announces the IND approval by China NMPA for its next-generation EGFR-Exon20ins inhibitor ABSK112 abbisko.com ↗
27 October 2023, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that ABSK112, a next-generation small molecule EGFR-Exon20ins inhibitor, has obtained clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China, and the company will soon launch a Phase I clinical trial for the treatment of patients with non-small cells lung cancer (NSCLC) in China. |
| 2023-07-05 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutic announces the IND approval by U.S. FDA for its next-generation EGFR-Exon20 inhibitor ABSK112 abbisko.com ↗
4 July 2023, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) announced that the U.S. Food and Drug Administration (FDA) has approved the Phase I clinical trial of ABSK112 for the treatment of patients with NSCLC. |
| 2023-04-17 | Abbisko Therapeutics Co, Ltd | Results Abbisko presents 5 research results at the 2023 AACR Annual Meeting abbisko.com ↗
Abbisko (Stock Code: 2256.HK) announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Abbisko Therapeutics Co, Ltd | 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 (pan-KRAS) abbisko.com ↗ |
| 2024-02-23 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112 abbisko.com ↗ |
| 2023-10-27 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutic announces the IND approval by China NMPA for its next-generation EGFR-Exon20ins inhibitor ABSK112 abbisko.com ↗ |
| 2023-07-05 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutic announces the IND approval by U.S. FDA for its next-generation EGFR-Exon20 inhibitor ABSK112 abbisko.com ↗ |
| 2023-04-17 | Abbisko Therapeutics Co, Ltd | Abbisko presents 5 research results at the 2023 AACR Annual Meeting abbisko.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06225804 ↗ |
| Action | Inhibit | “EGFR Exon20 inhibitor” NCT06225804 ↗ |
| Route | Oral | “oral ABSK112” NCT06225804 ↗ |
| Target | EGFR | “EGFR Exon20 inhibitor” NCT06225804 ↗ |